Articles

New model aims to ease transition from fee-for-service to value-based cancer care delivery using an oncology medical home framework and performance-based reimbursement that includes monthly care management payments. Read More ›

Incident cases of ovarian cancer differed little between ever users and never users of powder with no dose-response relationship. Read More ›

“This is truly a practice-changing study, not just for our patients but for the design of other studies. We can successfully identify candidates for olaparib. We saw a clinically meaningful improvement in outcomes for patients with HRR genetic alterations, driven mainly by BRCA2,” said Eleni Efstathiou, MD, PhD. Read More ›

It is estimated that 350 million people worldwide use biologics on a regular basis to treat their medical conditions. These therapies are incredibly innovative and have expanded the arsenal of effective treatment options for cancer, rheumatoid arthritis, and other serious illnesses. However, the high costs of these therapies, although understandable, can create access issues for patients. That is why biosimilars are so important.

Read More ›

Although performance category weightings remain unchanged from 2019, the Centers for Medicare & Medicaid Services has raised the bar for participating providers by increasing the performance threshold from 30 to 45 points in 2020. Read More ›

The use of combination therapies in the first- and second-line settings for advanced ovarian cancer has the potential to improve patient outcomes. Read More ›

Although federal reform efforts are likely to stall in the Senate, legislation prohibiting gag clauses, claw backs, and price spreading are being passed at the state level. Read More ›

Patients and healthcare providers should be aware of the toxicities that may occur with the use of PARP inhibitors so that they can manage them appropriately. Read More ›

St. Luke’s Cancer Institute, Boise, ID, is celebrating its 50th anniversary this year. Formerly known as Mountain States Tumor Institute, St. Luke’s employs medical and radiation oncology specialists, as well as fellowship-trained cancer surgeons in areas such as thoracic, hepatobiliary, gynecologic, and urologic oncology. The facility also offers autologous and allogeneic bone marrow and stem-cell transplantation and is a National Marrow Donor Program Apheresis Center. In addition, St. Luke’s is home to Idaho’s only pediatric cancer program and federally sponsored hemophilia center.

Read More ›